Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cetraxate SCHEMBL7616457 | 1.00 | F2 (1.00) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL20774010 | 1.00 | F2 (1.00) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL19437 | 1.00 | F2 (1.00) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL11215307 | 0.99 | F2 (0.97) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL10789557 | 0.99 | F2 (0.97) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL11215310 | 0.99 | F2 (0.97) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL144286 | 0.99 | F2 (0.97) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL144285 | 0.99 | F2 (0.97) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL4639111 | 0.99 | F2 (0.97) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL1649792 | 0.97 | F2 (0.95) | F2HTTKMT2ASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220330541-A1 | Methods for the Preservation of Reagent Red Blood Cells Using Carbon Monoxide | HEMANEXT INC. (US) | 2022-10-20 | — | — | US | claimed |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | claimed |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | ACORDA THERAPEUTICS, INC. | 2020-05-21 | — | — | US | claimed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014111957-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | SATYAM APPARAO (IN) | 2014-07-24 | — | — | WO | claimed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| US-20110212927-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. (US) | 2011-09-01 | — | — | US | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061537-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5908824-A | DISPERSED HOMOGENEOUSLY IN AND ADSORBED HOMOGENEOUSLY ONTO A MUCOSA PROTECTING AND/OR TISSUE REPAIRING AGENT | DOTT RESEARCH LABORATORY (JP) | 1999-06-01 | — | — | US | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| EP-0770390-A1 | Nasally administrable compositions containing physiologically active peptides | DOTT RESEARCH LABORATORY (JP) | 1997-05-02 | — | — | EP | claimed |
| EP-0591546-A1 | EXTERNAL PREPARATION FOR CURING DAMAGE TO SKIN | DOTT LIMITED COMPANY (JP) | 1994-04-13 | — | — | EP | claimed |
| US-4147876-A | CHEMICAL INTERMEDIATE FOR ANTIULCER AGENTS AND ENZYME INHIBITORS | DAIICHI SEIYAKU CO., LTD. (JP) | 1979-04-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212927-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | F2 3207/4885HTT 4037/4885KMT2A 2173/4885 |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | F2 3207/4885HTT 4037/4885KMT2A 2173/4885 |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | F2 3207/4885HTT 4037/4885KMT2A 2173/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | F2 1609/4885HTT 4296/4885KMT2A 3867/4885 |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | F2 2360/4885HTT 2769/4885KMT2A 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.